KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib

Significant challenges to develop selective and effective pharmacological inhibitors for important oncoproteins like RAS continue impeding the success to treat cancers driven by such mutations. In the present study, the ABT263 and axitinib combination imposed synergistic effects on RAS-mutant colon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guihua, Huang, Ying, Wu, Zhipeng, Zhao, Chunmei, Cong, Hui, Ju, Shaoqing, Wang, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400663/
https://www.ncbi.nlm.nih.gov/pubmed/30674639
http://dx.doi.org/10.1042/BSR20181786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400663/
https://www.ncbi.nlm.nih.gov/pubmed/30674639
http://dx.doi.org/10.1042/BSR20181786

Ejemplares similares